Following your request for information under Freedom of Information Act 2000 which we received on 23rd January 2014 we are providing you information as held by Chelsea and Westminster Hospital NHS Foundation Trust.

In your query, you requested the information about specific treatments under NICE guidelines and the Trust answers as below.

1. The four treatments listed in query routinely available to patients under the indications specified by the NICE TAGs
   - Ranibizumab given for i) wet AMD and ii) DMO, in accordance with the appropriate NICE guidelines
   - Ocriplasmin is yet to gain approval at the Trust’s Medicine Committee
   - Aflibercept is available in the Trust’s formulary but has not yet been used
   - Ozurdex is given for vein occlusion (usually for DMO + uveitis)

2. Details of any additional criteria to the TAG criteria / interpretation of the TAG criteria which is placed on the availability of these four treatments

   There are no additional criteria

3. The number of patients treated with each treatment in line with the indication specified in the TAG since the time when each treatment should have been available to patients

   Figures are only available from mid November 2013 when treatments moved into Outpatient environment. Before this time, patients were given injection treatment in day case theatre lists with the same access as they now are so it can be assumed that rates of injection have remained constant. All injections below are Lucentis (Ranibizumab) treatments. Numbers are described as below.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Macular Oedema</th>
<th>Diabetic Macular Oedema</th>
</tr>
</thead>
<tbody>
<tr>
<td>November 2013</td>
<td>18</td>
<td>1</td>
</tr>
<tr>
<td>December 2013</td>
<td>28</td>
<td>17</td>
</tr>
<tr>
<td>January 2014</td>
<td>38</td>
<td>23</td>
</tr>
<tr>
<td>February 2014(14/02/14)</td>
<td>13</td>
<td>7</td>
</tr>
</tbody>
</table>

4. The number of Individual Funding Requests made for each treatment since the date when the treatment should have been made available to patients

   None as required
5. Meeting minutes of meetings since November 2012 in which the approval of use of that treatment has been discussed

The minutes of the Trust’s Medicines Committee meeting are available in public domain via the Trust’s website http://www.chelwest.nhs.uk/

We trust the above information is satisfactory to you.

If you are not happy with the way in which your request has been dealt with or are dissatisfied with this response and wish to appeal, please write to Information Governance Manager at information.governance@chelwest.nhs.uk. Your complaint will be dealt with through our internal review process.

If you are still not satisfied following the Internal Review, you have a right to complaint to the Information Commissioner’s Office. He can be contacted at casework@ico.org.uk.

Re-use of Public Sector Information

All information supplied by the Trust in answering a request for information under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2005, Statutory Instrument 2005 No.1515 which came into force on 1st July 2005.

Under the terms of the Regulations, the Trust will license the re-use of any or all information supplied if being used in a form and for a purpose other than which it was originally supplied. However, The Trust reserves the right, in certain circumstances, to charge a fee for the re-use of some information which it deems to be of commercial value.

Yours sincerely

Aung Tun
Information Governance Analyst